title: Ibrutinib-Induced Lymphocytosis: Cytological Features.
authors.affiliation: Service d'Hématologie, Centre Hospitalier Lyon-Sud/Hospices Civils de Lyon, Pierre-Bénite, France.
authors.forename: Adrien
authors.initials: A
authors.lastname: Quintela
authors.forename: Pierre
authors.initials: P
authors.lastname: Sujobert
authors.forename: Evelyne
authors.initials: E
authors.lastname: Callet-Bauchu
authors.forename: Gilles
authors.initials: G
authors.lastname: Salles
authors.forename: Lucile
authors.initials: L
authors.lastname: Baseggio
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000077329:Agammaglobulinaemia Tyrosine Kinase; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002869:Chromosome Aberrations; D005260:Female; D015870:Gene Expression; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D018655:Lymphocyte Count; D008218:Lymphocytosis / Q000139:chemically induced / Q000175:diagnosis* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010880:Piperidines; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D011720:Pyrazoles / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011743:Pyrimidines; C551803:ibrutinib; D011505:Protein-Tyrosine Kinases; D000077329:Agammaglobulinaemia Tyrosine Kinase; D000225:Adenine